Sort   by:  
 Page size 
ProteomicsInteraction with ribosomal proteins accompanies ER stress-induction of the anticancer metallodrug BOLD-100/KP1339
The ruthenium-based anticancer agent BOLD-100/KP1339 has shown promising results in several in vitro and in vivo tumour models, as well as in early clinical trials. However, its mode of action remains to be fully elucidated. Recent evidence identified ER stress-induction and concomitant down-modulat...
ORGANISM(S): Homo sapiens (Human) 
2021-06-01 | PXD022449 | Pride
Bold-100 Proteomics Kp1339 Target identification Anticancer agents 
ClinicalBOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX ch...
2341799 | ecrin-mdr-crc
TranscriptomicsThe anticancer Ruthenium drug BOLD-100 regulates apoptosis of BRAFMT colorectal cancer cells through modulation of the AhR/ROS/ATR signalling axis.
The understanding of how oncogenes modulate the mechansim of action of compounds relies on interrogating acute and longer transcriptional changes following treatment. We report here the transcriptional profiles of an isogenic cell line model VACO432 (BRAFMT V600E/WT) and VT1 (BRAFWT/-) following 3H ...
ORGANISM(S): Homo sapiens 
2024-01-10 | GSE252858 | GEO
UnknownSynthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100.
Not available
S-EPMC10674160 | biostudies-literature
GenomicsThe anticancer Ruthenium drug BOLD-100 regulates apoptosis of BRAFMT colorectal cancer cells through modulation of the AhR/ROS/ATR signalling axis.
The anticancer Ruthenium drug BOLD-100 regulates apoptosis of BRAFMT colorectal cancer cells through modulation of the AhR/ROS/ATR signalling axis.
PRJNA1062832 | ENA
UnknownThe Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation.
Not available
S-EPMC10646284 | biostudies-literature
UnknownUnraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study.
Not available
S-EPMC12310764 | biostudies-literature
UnknownThe Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.
Not available
S-EPMC8875291 | biostudies-literature
UnknownRuthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation.
Not available
S-EPMC7616621 | biostudies-literature
UnknownTherapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma.
Not available
S-EPMC12164152 | biostudies-literature
Sort   by:  
 Page size